Moody Lynn & Lieberson LLC Invests $1.94 Million in AstraZeneca PLC $AZN

Moody Lynn & Lieberson LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 25,322 shares of the company’s stock, valued at approximately $1,943,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. NewSquare Capital LLC boosted its holdings in shares of AstraZeneca by 149.3% in the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares during the last quarter. Richardson Financial Services Inc. increased its holdings in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares during the last quarter. FSA Wealth Management LLC boosted its holdings in AstraZeneca by 376.0% in the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after acquiring an additional 376 shares during the last quarter. VSM Wealth Advisory LLC purchased a new stake in AstraZeneca during the second quarter valued at about $33,000. Finally, Maseco LLP acquired a new stake in AstraZeneca during the second quarter worth about $34,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AstraZeneca stock opened at $92.51 on Wednesday. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $94.01. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market cap of $286.92 billion, a P/E ratio of 30.73, a price-to-earnings-growth ratio of 1.72 and a beta of 0.31. The stock has a 50 day moving average of $88.70 and a 200-day moving average of $80.80.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.05. The firm had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.08 earnings per share. On average, analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AZN shares. Guggenheim restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Cowen reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Jefferies Financial Group started coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, HSBC restated a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a report on Wednesday, December 10th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.